To improve the bioavailability and efficacy, a second generation of ALDH1A1 inhibitor, NCT-505, was discovered, which exhibits high enzymatic potency and cellular activity in various cancer cell lines with a high selectivity in inhibiting ALDH1A1 over other ALDH isozymes18. The gene discussed is LDHA; the disease is cancer.